UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)), Metastatic Breast Cancer Patients: A Phase II Feasibility Study

Grant

Date/time Interval

  • April 19, 2011 - April 18, 2013
  • Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • 07
  • Contributor

  • Lisle Nabell M.D.   Principal Investigator